Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor

Published:2016-05-26 Issue:9 Volume:72 Page:1065-1073
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Ayalasomayajula Surya P.,Langenickel Thomas H.,Jordaan Pierre,Zhou Wei,Chandra Priyamvada,Albrecht Diego,Pal Parasar,Rajman Iris,Sunkara Gangadhar

Funder

Novartis AG, Basel

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-016-2072-7.pdf

Reference17 articles.

1. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP (2010) Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 50(4):401–414

2. Shi J, Wang X, Nguyen J, Wu AH, Bleske BE, Zhu HJ (2016) Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation. Drug Metab Dispos 44(4):554–559. doi: 10.1124/dmd.115.068536

3. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. doi: 10.1056/NEJMoa1409077

4. Ayalasomayajula S, Langenickel T, Chandra P, Wolfson E, Albrecht D, Zhou W, Parasar P, Rajman I, G S (2016) Effect of food on the oral bioavailability of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects. Int J Clin Pharmacol Ther (Accepted)

5. Flarakos J, Du Y, Bedman T, Al-Share Q, Jordaan P, Chandra P, Albrecht D, Wang L, Gu H, Einolf HJ, Huskey SE, Mangold JB (2016) Disposition and metabolism of [C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects. Xenobiotica: 1-15 DOI 10.3109/00498254.2015.1014944

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of a sensitive and simple LC-MS/MS method for simultaneous quantitation of valsartan, sacubitril and sacubitrilat in pediatric population;Journal of Pharmaceutical and Biomedical Analysis;2024-01

2. Renin Angiotensin Aldosterone System Blockers;Hypertension;2024

3. Devastating Worsening Renal Function Following the Initiation of Sacubitril/Valsartan: Falling Between Two Stools;Cureus;2023-10-09

4. Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists;Cardiology and Therapy;2023-06-29

5. Sacubitril/Valsartan in Dialysis Patients: Update on Current Perspectives;Cardiovascular Drugs and Therapy;2023-06-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3